PF-04691502 demonstrated antitumor activities in ovarian and glioblastoma tumor xenograft models derived from cancer cell lines carrying either a PTEN deletion or PIK3CA mutation [11] and in a genetically engineered mouse model of ovarian cancer driven by a Kras mutation and Pten deletion [12]. This evidence concerns the gene PTEN and neoplasm.